DE69732492D1 - Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden - Google Patents
Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werdenInfo
- Publication number
- DE69732492D1 DE69732492D1 DE69732492T DE69732492T DE69732492D1 DE 69732492 D1 DE69732492 D1 DE 69732492D1 DE 69732492 T DE69732492 T DE 69732492T DE 69732492 T DE69732492 T DE 69732492T DE 69732492 D1 DE69732492 D1 DE 69732492D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- depressions
- accompanied
- heavy
- receptor antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 238000011970 concomitant therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9625051 | 1996-12-02 | ||
GB9625051A GB9625051D0 (en) | 1996-12-02 | 1996-12-02 | Therapeutic agents |
GB9701459 | 1997-01-24 | ||
GB9701459A GB9701459D0 (en) | 1997-01-24 | 1997-01-24 | Therapeutic agents |
GB9713715A GB9713715D0 (en) | 1997-06-27 | 1997-06-27 | Therapeutic agents |
GB9713715 | 1997-06-27 | ||
GBGB9716472.7A GB9716472D0 (en) | 1997-08-04 | 1997-08-04 | Therapeutic agents |
GB9716472 | 1997-08-04 | ||
GBGB9721177.5A GB9721177D0 (en) | 1997-10-07 | 1997-10-07 | Therapeutic use |
GB9721177 | 1997-10-07 | ||
PCT/EP1997/006686 WO1998024441A1 (en) | 1996-12-02 | 1997-11-25 | Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69732492D1 true DE69732492D1 (de) | 2005-03-17 |
DE69732492T2 DE69732492T2 (de) | 2006-03-30 |
Family
ID=27517385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69732492T Expired - Fee Related DE69732492T2 (de) | 1996-12-02 | 1997-11-25 | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0941093B1 (de) |
JP (1) | JP2001504850A (de) |
AT (1) | ATE288756T1 (de) |
AU (1) | AU736042B2 (de) |
CA (1) | CA2273800A1 (de) |
DE (1) | DE69732492T2 (de) |
ES (1) | ES2236838T3 (de) |
WO (1) | WO1998024441A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999064010A1 (en) * | 1998-06-11 | 1999-12-16 | Merck Sharp & Dohme Limited | Use of a nk-1 receptor antagonist for treating psychiatric disorders |
WO1999064006A1 (en) * | 1998-06-11 | 1999-12-16 | Merck Sharp & Dohme Limited | Use of a nk-1 receptor antagonist for treating psychiatric disorders |
UA90708C2 (ru) | 2005-02-25 | 2010-05-25 | Ф. Хоффманн-Ля Рош Аг | Таблетки с улучшенной дисперсностью лекарственного вещества |
EP2129381A1 (de) | 2007-01-24 | 2009-12-09 | Glaxo Group Limited | Pharmazeutische zubereitungen enthaltend 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazin or r(-)-2,4-diamino-5-(2,3dichlorophenyl)-6-fluoromethyl pyrimidin und einen nk1- rezeptor-antagonisten |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
IL111002A (en) * | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | History of piperidine, their preparation and the pharmaceutical preparations containing them |
SK283070B6 (sk) * | 1993-12-29 | 2003-02-04 | Merck Sharp & Dohme Limited | Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
DK0777659T3 (da) * | 1994-08-15 | 2001-09-03 | Merck Sharp & Dohme | Morpholinderivater og deres anvendelse som terapeutiske midler |
-
1997
- 1997-11-25 WO PCT/EP1997/006686 patent/WO1998024441A1/en active IP Right Grant
- 1997-11-25 DE DE69732492T patent/DE69732492T2/de not_active Expired - Fee Related
- 1997-11-25 AU AU55591/98A patent/AU736042B2/en not_active Ceased
- 1997-11-25 JP JP52517298A patent/JP2001504850A/ja not_active Ceased
- 1997-11-25 EP EP97952021A patent/EP0941093B1/de not_active Revoked
- 1997-11-25 CA CA002273800A patent/CA2273800A1/en not_active Abandoned
- 1997-11-25 AT AT97952021T patent/ATE288756T1/de not_active IP Right Cessation
- 1997-11-25 ES ES97952021T patent/ES2236838T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1998024441A1 (en) | 1998-06-11 |
EP0941093B1 (de) | 2005-02-09 |
JP2001504850A (ja) | 2001-04-10 |
ES2236838T3 (es) | 2005-07-16 |
ATE288756T1 (de) | 2005-02-15 |
DE69732492T2 (de) | 2006-03-30 |
AU736042B2 (en) | 2001-07-26 |
EP0941093A1 (de) | 1999-09-15 |
CA2273800A1 (en) | 1998-06-11 |
AU5559198A (en) | 1998-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE418986T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems welche einen nicotin-analog und einen acetylcholinesterase inhibitor enthalten | |
CY1118924T1 (el) | Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας | |
DK0668863T3 (da) | Quinuclidinderivat som substans P-antagonist | |
PT893992E (pt) | Formas de dosagem oral de desintegracao rapida | |
ATE398618T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten | |
ATE269336T1 (de) | Steroidrezeptor-modulator verbindungen und methoden | |
ATE175114T1 (de) | Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten | |
SE9704644D0 (sv) | New use | |
ES2087038B1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa | |
ATE320832T1 (de) | Behandlung von haarfollikeln mit neurokinin 1 rezeptor antagonisten | |
BG105962A (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
RU2001124802A (ru) | Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств | |
EE200100520A (et) | N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena | |
MXPA03000439A (es) | Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida. | |
DE69731658D1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen | |
AP2002002501A0 (en) | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. | |
SE9903995D0 (sv) | New combination | |
DE69732492D1 (de) | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden | |
NZ535611A (en) | Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist | |
ATE282416T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen | |
DE60028928D1 (de) | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt | |
SE9302218D0 (sv) | New use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8339 | Ceased/non-payment of the annual fee |